Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681079 · ClinicalTrials.gov registry record
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
A clinical trial, sponsored by Theravance Biopharma.
- Completed
- Registry status
- 14
- Enrollment target
NCT04681079: Completed study, sponsored by Theravance Biopharma.
NCT04681079 is a clinical trial that has completed, run by Theravance Biopharma. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04681079 has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.
Primary Outcome
Change in viral load from baseline at each sample point (room air and surfaces). This outcome measure is listed as exploratory in the protocol.
Interventions
- DRUG albuterol sulfate (MDI)
- DRUG albuterol sulfate (nebulizer)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2022-01-18 |
What the finished NCT04681079 record still lists
NCT04681079 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which albuterol sulfate (MDI) is the first listed.
NCT04681079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04681079 about?
NCT04681079 is a clinical study titled "Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19". A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.
What is the current status of trial NCT04681079?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2021-05-04. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04681079?
The interventions under investigation include: albuterol sulfate (MDI) (DRUG), albuterol sulfate (nebulizer) (DRUG).
Who is sponsoring clinical trial NCT04681079?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy